A randomized, open label study of the effect of MabThera [rituximab; Rituxan] on quality of life (QOL) and treatment response in patients with rheumatoid arthritis.
Phase of Trial: Phase IV
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Disease-modifying antirheumatics; Methotrexate; Rituximab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Planned number of patients changed from 98 to 138 as reported by Roche record.
- 19 Jun 2008 New trial record.